Related Posts Plugin for WordPress, Blogger...


Last week I attended the 2013 Innovation Conference put on by NEHI (a fellow Cambridge, MA based group) with the theme, Patient Engagement 360. It was a fantastic conference, with a lot of smart people with a lot of great ideas on how to activate patients to participate in their healthcare. One of the speakers, Dr. Judith Hibbard, Professor of Health at the University of Oregon described a metric that was derived from her research, called the Patient Activation Measure, or the PAM Score. Follow the link to access the full Health Services Research report and this link for various follow up work that Dr. Hibbard has written on the subject.

The idea is that through a series of simple questions that a patient answers, a score can be applied to the patient that measures their level of participation in their own healthcare. They found that those patients that are activated, or had a high PAM score, cost the health system less and in general have better health outcomes.

So, in theory, if initiatives are put in place to raise the PAM score of patients, a health plan or health system can lower their costs and improve patient outcomes.

A direct link to ROI! As we’ve said in the past, that is how data needs to be used!

We are big fans of scoring metrics here at AdverseEvents, Inc. While not quite ready to reveal the fine details in a public blog, one of the many analytics we have been working on is a scoring methodology that uses post-marketing safety data to determine costs that result from drug side-effects.

Besides the stand-alone utility to understanding the full cost of a medication to the healthcare system, we found a very significant correlation to another tool we’ve developed- the ability to signal that an FDA alert will be issued on a drug, on average 3.5 years in advance of any action.

The tie in occurs between our signal point and where FDA action occurs… We see a 349% jump in adverse event related costs and negative outcomes.

So, in theory, if initiatives are put in place to flatten this curve during the critical time between when our signal occurs and the FDA takes action, a health plan or health system can lower their costs and improve patient outcomes.

We love talking ROI. To learn more about our analytics, please do not hesitate to contact us.

 

Post FDA approval drug safety whitepaper - Download Now



Jim Davis

Jim Davis

Executive Vice President

Jim Davis LinkedinJim Davis Twitter

 

Topics: FDA

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.